Our finding that gRNA-directed targeting of NEMO promoter B does not substantially affect liver-specific (promoter D) expression of NEMO (Fig 6) suggests that targeting of the core promoter B sequence for the treatment of cancers that rely on canonical NF-κB signaling would not affect liver function in vivo. The gene discussed is NFKB1; the disease is cancer.